Skip to main content
Equibles
SILO logo

SILO · Silo Pharma, Inc. · Metrics

Track SILO — free

Use SILO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SILO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.10 0.00 (-0.19%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — cleared Aug 13, 2026

The latest filing states the doubt was alleviated.

“The positive working capital and the July 2026 Private Placement (see Note 9) serve to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern. The Company believes that it has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.”
View the 10-Q filed Aug 13, 2026
Market Cap
$3.34M
Shares
1.59M

SILO metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.10
Market cap
$3.34M

Price action

20 metrics
Price change (1W)
-14.1%
Price change (30D)
-34.7%
Price change (3M)
-67.3%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
97.3%
Annualized volatility (3M)
99.5%
Beta
—
RSI (14D)
19.5
Price vs SMA 50
-47.0%
Price vs SMA 200
—
Avg volume (3M)
193,533
Relative volume
0.1
Average dollar volume
$973,485

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.59M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
61.8×
reciprocal yield 1.6%
P / book
0.7
reciprocal yield 146.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-133.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-14.8%
Operating margin
-5,937.0%
Trailing 12 months
Net margin
-5,863.5%
Gross profit (TTM)
−$7,987
Operating profit (TTM)
−$4.46M
Net income (TTM)
−$4.47M
Trailing 12 months
Diluted EPS (TTM)
$-3.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$106.52

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$54,077
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+162.4%
Year over year · more shares
Revenue CAGR (3Y)
+0.0%
Revenue CAGR (5Y)
+12.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-91.5%
Return on assets
-75.1%
Debt / equity
—
Current ratio
5.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-112.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$5.23M
Latest balance sheet
Cash & equivalents
$3.28M
Total assets
$5.95M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.34M
Capital expenditures (TTM)
—
R&D (TTM)
$2.16M
SG&A (TTM)
$200,936
Stock compensation (TTM)
$195,369
R&D / revenue
—
Stock compensation / revenue
361.3%

Ownership (13F)

3 metrics
13F filers
9
13F filer change QoQ
-6
Institutional ownership
9.0%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
36 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1514183 CUSIP 82711P300 13F (30d) 1 filings 1 filers Visit website